ClinicalTrials.gg
RecruitingNCT05438121STABLE-DCBUpdated Oct 15, 2024

STabilization of Atheroma by Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB)

An observational study in Coronary Artery Disease, Atherosclerotic Plaque and De Novo Stenosis, sponsored by Korea University Ansan Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Korea University Ansan Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
65
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 361 studies in Coronary Artery Disease with a site in Korea, Republic of — 81 open to participants now, 103 under way, 2 of them phase 3. Coronary Artery Disease · Korea, Republic of.

Planned enrollment
142nd of 152
65 · median 1,113
Started
2022
with 24 others
Observational
153 of 361
40 open now
Primary completion
2025-06
later than 15 of 102 live
Registered
276th of 361
by date

Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, this one is the 142nd largest by planned enrollment of the 152 observational ones that give a count, is one of 25 that started in 2022, is one of 153 observational ones, reaches primary completion later than 15 of the 102 other live ones, and was the 276th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

81 of the 361 studies in Coronary Artery Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Coronary Artery Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aims to investigate whether DCB angioplasty, compared to statin-based medical treatment alone, will lead to more reduction in plaque lipid burden as assessed by near infrared spectroscopy (NIRS) at 6-9 months following the index procedure.

Read the detailed description

A large lipid core is the hallmark of coronary plaques at risk of rupture and subsequent atherothrombosis. Although statin-based medical treatment is known to regress and stabilize lipid-rich coronary plaques, it takes time for such beneficial effects to appear. This study aims to investigate whether DCB angioplasty can effectively modify de novo coronary atherosclerotic plaque and lead to reduction in plaque lipid burden as assessed by near infrared spectroscopy (NIRS) at 6-9 months following the index procedure.

03

Conditions studied

  • Coronary Artery Disease
  • Atherosclerotic Plaque
  • De Novo Stenosis

Keywords

  • drug coated balloon
  • Near infrared spectroscopy
  • NIRS-IVUS
  • De novo coronary lesion
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with significant multi-vessel coronary artery disease requiring revascularization

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with significant multivessel coronary artery disease requiring revascularization
  • Any De novo lesions (reference vessel diameter of 2.25mm\~4.0mm) suitable for DCB angioplasty
  • Lesion suitable for intravascular imagings
  • Written

Exclusion criteria

Exclusion Criteria:

  • Hemodynamically unstable or cardiogenic shock
  • Left main stenotic lesion or graft vessel lesion
  • Visible angiographic thrombus, not resolved by balloon angioplasty
  • Pregnancy or breastfeeding
  • Comorbidities with \< 12 months
  • Severe coronary calcification or tortuosity, hindering timely DCB delivery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
65 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with multivessel CAD undergoing DCB PCI

    I. Patients with significant multi-vessel coronary artery disease will be screened. II. If the patient is found to have at least one lipid-rich plaque (LRP, LCBI\>250) requiring revascularization (DS\>70%) will undergo multi-vessel IVUS-NIRS imaging. III. If multi-vessel NIRS screening revealed another LRP (LCBI\>250) with DS\<70%, the patient will be enrolled. IV. The stenotic LRP lesion (DS\>70%) will be subjected to DCB angioplasty while non-stenotic LRP lesion (DS\<70%) will be left unintervened and treated medically. V. Comparative lesions: 1. DCB-treated LRP (DS\>70%, maxLCBI\>250) 2. Unintervened, medically-treated LRP (DS\<70%, maxLCBI\>250)

    Device: SeQuent Please Neo

Interventions

  • DeviceSeQuent Please Neo

    DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.

06

What researchers measure

Primary outcomes

  1. Difference of serially-assessed lipid core burden index (LCBI) change between DCB-treated lesion vs. medically-treated lesion

    ΔLCBI: NIRS-assessed changes in LCBI between baseline and follow-up.

    Time frame: 6~9 month

Secondary outcomes

  1. Difference of serially-assessed plaque burden change between DCB-treated lesion vs. medically-treated lesion.

    ΔPlaque burden: IVUS-assessed changes in plaque burden between baseline and follow-up.

    Time frame: 6~9 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kleber FX, Mathey DG, Rittger H, Scheller B; German Drug-eluting Balloon Consensus Group. How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention. 2011 May;7 Suppl K:K125-8. doi: 10.4244/EIJV7SKA21. No abstract available. PubMed 22027722 ↗
  • Her AY, Shin ES, Bang LH, Nuruddin AA, Tang Q, Hsieh IC, Hsu JC, Kiam OT, Qiu C, Qian J, Ahmad WAW, Ali RM. Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific Consensus Group. Cardiol J. 2021;28(1):136-149. doi: 10.5603/CJ.a2019.0093. Epub 2019 Sep 30. PubMed 31565793 ↗
  • Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar 10;75(9):1061-1073. doi: 10.1016/j.jacc.2019.12.046. PubMed 32138967 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jun 2025, 32 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 32 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Jun 29, 2022
StartActual
Oct 13, 2022
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 31, 2026
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05438121
Lead sponsor
Korea University Ansan Hospital
Collaborators
B. Braun Korea Co., Ltd.
Responsible party
Sunwon Kim (Sunwon Kim, MD, PhD, Associate professor, Korea University Ansan Hospital) — Principal investigator
First posted
Jun 29, 2022
Start date
Oct 13, 2022
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 15, 2024

Study contacts

Sunwon Kim, MD, PhD
Contact
sunwon11@hanmail.net
82-31-8099-6349
Sunwon Kim, MD, PhD
principal investigator · Korea University Ansan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion